The FDA has approved paltusotine, a selectively targeted somatostatin receptor type 2 nonpeptide agonist, for first-line treatment of certain patients with acromegaly, Crinetics Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback